2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow KPT-9274: new trials by email Literature Review of KPT-9274 trials Research Report on KPT-9274
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia KPT-9274 - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Completed | University of Colorado, Denver | 16 | 2021-08-27 | 2026-01-27 |
| A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma ATG-019, ATG-019 + Niacin ER - Solid Tumor, Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Antengene Therapeutics Limited | 20 | 2020-04-13 | 2024-04-30 |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) KPT-9274, Niacin ER, Nivolumab - Solid Tumors, NHL | Phase 1 | Terminated | Karyopharm Therapeutics Inc | 60 | 2016-06-08 | 2024-11-25 |
Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1)
Antengene Therapeutics Limited (1) · Karyopharm Therapeutics Inc (1) · University of Colorado, Denver (1)
United States (2) · Canada (1) · China (1) · Taiwan (1)
Daniel Pollyea, MD (1) · Stephen Xie, MD; PhD (1)
PMID 28062705, PMID 32822582, PMID 34253597, PMID 37864885, PMID 41824279